HC Wainwright & Co.：重申Nektar Therapeutics评级

证券之星

01-13

HC Wainwright&Co.：重申Nektar Therapeutics(NKTR.US)评级，由买入调整至买入评级,目标价由6.50美元调整至6.50美元。内克塔治疗(NKTR.US)公司简介：内克塔治疗是一家以研究为基础的生物制药公司，致力于在未满足医疗需求的领域发现和开发药物。其研究和开发的新研究药物包括肿瘤学，免疫学和病毒学治疗。该公司专注于使用新的化学方法来制造治疗癌症和自身免疫...

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503305652"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503305652\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503305652?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-01-13 20:13","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2503305652","market":"us","top_or_hot":-1,"title":"HC Wainwright & Co.：重申Nektar Therapeutics评级","media":"证券之星","content":"<div>\n<p>HC Wainwright&Co.：重申Nektar Therapeutics(NKTR.US)评级，由买入调整至买入评级,目标价由6.50美元调整至6.50美元。内克塔治疗(NKTR.US)公司简介：内克塔治疗是一家以研究为基础的生物制药公司，致力于在未满足医疗需求的领域发现和开发药物。其研究和开发的新研究药物包括肿瘤学，免疫学和病毒学治疗。该公司专注于使用新的化学方法来制造治疗癌症和自身免疫...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113201513a2201d7e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HC Wainwright & Co.：重申Nektar Therapeutics评级</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHC Wainwright & Co.：重申Nektar Therapeutics评级\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-13 20:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113201513a2201d7e&s=b><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HC Wainwright&Co.：重申Nektar Therapeutics(NKTR.US)评级，由买入调整至买入评级,目标价由6.50美元调整至6.50美元。内克塔治疗(NKTR.US)公司简介：内克塔治疗是一家以研究为基础的生物制药公司，致力于在未满足医疗需求的领域发现和开发药物。其研究和开发的新研究药物包括肿瘤学，免疫学和病毒学治疗。该公司专注于使用新的化学方法来制造治疗癌症和自身免疫...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113201513a2201d7e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"内克塔治疗","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113201513a2201d7e&s=b","article_id":"2503305652","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113201513a2201d7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2503305652","pubTimestamp":1736770409,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"HC Wainwright&Co.：重申Nektar Therapeutics(NKTR.US)评级，由买入调整至买入评级,目标价由6.50美元调整至6.50美元。内克塔治疗(NKTR.US)公司简介：内克塔治疗是一家以研究为基础的生物制药公司，致力于在未满足医疗需求的领域发现和开发药物。其研究和开发的新研究药物包括肿瘤学，免疫学和病毒学治疗。该公司专注于使用新的化学方法来制造治疗癌症和自身免疫性疾病的药物。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"NKTR":"内克塔治疗","LENZ":"Therapeutics"},"translate_title":"HC Wainwright & Co.: Reaffirming Nektar Therapeutics Rating","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"NKTR":0.9},"content_text":"HC Wainwright&Co.：重申Nektar Therapeutics(NKTR.US)评级，由买入调整至买入评级,目标价由6.50美元调整至6.50美元。内克塔治疗(NKTR.US)公司简介：内克塔治疗是一家以研究为基础的生物制药公司，致力于在未满足医疗需求的领域发现和开发药物。其研究和开发的新研究药物包括肿瘤学，免疫学和病毒学治疗。该公司专注于使用新的化学方法来制造治疗癌症和自身免疫性疾病的药物。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}